Most HER-2-positive breast cancer patients are deemed to be at a high risk of relapse by current treatment guidelines and thus, nearly all patients are allocated to (neo)adjuvant trastuzumab and chemotherapy. Here, ERBB2 is linked to breast carcinoma.